RxDoctor Payments Data

Angela Bryant, PA

Physician Assistant · Longmont, CONPI 1750530986

Payments from drug & device makers

$1,948in general payments, 2019–2025

Across 97 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$446
  • AbbVie$271
  • Astellas Pharma US Inc$142
  • Boehringer Ingelheim$138
  • Lilly USA, LLC$121
  • AstraZeneca$118
  • plus $711 from 16 others

What the payments were for

  • Food & beverage$1,948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,948 in reported general payments places this provider in the 85th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$20,400
Medicare patients
55
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$70,631
EliquisApixaban29$39,257
TrulicityDulaglutide24$36,876
JardianceEmpagliflozin12$20,366
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,548
BelsomraSuvorexant11$5,010
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$3,015
SynthroidLevothyroxine Sodium14$1,735
Duloxetine Hcl34$1,552
Gabapentin61$1,458
Levothyroxine Sodium141$1,259
Bupropion XlBupropion Hcl37$1,119
Omeprazole39$979
Pregabalin18$957
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$102$70,63153 claims
Lilly USA, LLCTrulicity$121$36,87624 claims
Boehringer IngelheimJardiance$138$20,36612 claims
GSKTrelegy Ellipta$23$19,54816 claims
MerckBelsomra$25$5,01011 claims
AbbVieSynthroid$271$1,73514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Longmont

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →